THUR 180 Patient support program for RRMS patients treated with DMF

    loading  Checking for direct PDF access through Ovid


IntroductionIn the UK, the number of multiple sclerosis (MS) patients far exceeds the capacity of MS specialist nurses (MSSNs).MethodsBiogen and IQVIA developed a remote, nurse-led, script-based telephone line providing educational assistance and supporting treatment adherence among relapsing-remitting MS (RRMS) adult patients receiving delayed-release dimethyl fumarate (DMF; TECFIDERA). Following DMF initiation, 8 calls are scheduled over the first 3 months, followed by quarterly calls for the remainder of the first treatment year. The program began in March 2015; a new online treatment satisfaction survey started in July 2017.ResultsBased on summarized call data through November 2017, 941 total patients were enrolled from 136 UK hospitals, with a mean (median, range) of 6.9 (2, 1–117) patients/hospital. An average of 11.5 calls/patient were received. Across all 11 scheduled calls, the average time/call was 8.3 min. Over 33 months, cumulative DMF discontinuation among enrolled patients was 15.7%. Between July and November 2017, 31 patients on treatment for ≥1 year completed satisfaction surveys; 74% reported scores ≥4 (scale: 1 [poor] to 5 [excellent]).DiscussionThis program has been widely used and positively received across the UK by DMF-treated patients and may reduce the burden on MSSNs.SupportBiogen. Disclosures on poster.

    loading  Loading Related Articles